IL-22 Recombinant Rabbit mAb (SDT-716-344)

Interleukin-22 (IL-22), which was originally named IL-10-related T cell-derived inducible factor (IL-TIF), has generated considerable interest in recent years making it one of the best-studied members of the IL-10 family of cytokines, which also includes IL-10, IL-19, IL-20, IL-24 and IL-26, as well as the lambda-interferons IL-28A, IL-28B and IL-29. Unlike most cytokines, which target hematopoietic cells, the main impact of IL-22 is on non-hematopoietic epithelial cells and fibroblasts in tissues as diverse as lung, liver, kidney, thymus, pancreas, breast, gut, skin and the synovium. Although it can have a profound effect on the regeneration of epithelial tissues following injury, largely by promoting survival by inducing proliferation and inhibiting apoptosis of epithelial cells, this same function has also been implicated in pathological states such as malignancy and psoriasis. In addition, a role for IL-22 has also been described in host defense within barrier tissues such as the intestine, oral mucosa, skin and lung. Given this widespread action in regeneration, host defense and pathology, IL-22 is an attractive target for clinical development.